-+ 0.00%
-+ 0.00%
-+ 0.00%

ENHERTU® (FAM-TRASTUZUMAB DERUXTECAN-NXKI) APPROVED IN THE US FOR TWO NEW INDICATIONS FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER

Reuters·05/16/2026 01:52:00

Please log in to view news